Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060546 | 1.00 | NPC1 (0.65) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL27458682 | 0.94 | NPC1 (0.59) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL14699615 | 0.83 | RAB9A (0.55) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL14699621 | 0.83 | RAB9A (0.55) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL31702246 | 0.80 | TRPA1 (0.86) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL3364649 | 0.80 | TRPA1 (0.86) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL70162 | 0.80 | TRPA1 (0.86) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL70163 | 0.80 | TRPA1 (0.86) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL2474219 | 0.80 | LMNA (0.61) | NPC1POLBKMT2AMEN1MAPT | |
| SCHEMBL2474220 | 0.80 | LMNA (0.61) | NPC1POLBKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | CORNELL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12180551-B2 | Method of using biomarkers and clinical variables for predicting chemotherapy benefit | MYRIAD INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| US-20230210916-A1 | Bacteriocin Production, Compositions and Methods of Use | ISOTHRIVE INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230116885-A1 | METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT | MYRIAD GENETICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11505832-B2 | Method of using biomarkers and clinical variables for predicting chemotherapy benefit | MYRIAD GENETICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11246893-B2 | Bacteriocin production, compositions and methods of use | ISOTHRIVE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-0867719-A1 | Method and kit for testing polyolester lubricants used in refrigerant compressors | THERMO KING CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5707871-A | REACTION OF TRIMETHYLOLPROPANE WITH MIXTURE OF BRANCHED AND LINEAR ACIDS | THERMO KING CORPORATION (US) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | KHK, GCK, FN3K | NPC1 1965/4885POLB 3870/4885KMT2A 1229/4885 |
| US-20230210916-A1 | Bacteriocin Production, Compositions and Methods of Use | SCTR, GRPR, BMPR2 | NPC1 2839/4885POLB 2530/4885KMT2A 4500/4885 |
| US-11246893-B2 | Bacteriocin production, compositions and methods of use | SCTR, GRPR, BMPR2 | NPC1 2839/4885POLB 2530/4885KMT2A 4500/4885 |
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | FABP2, PKN2, APC | NPC1 1845/4885POLB 1825/4885KMT2A 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.